CLLS - Multiplikator forward rega marang pendapatan cellectis.com

Cellectis S.A. is a French leader in gene editing that attracts top scientists through its unique laboratory infrastructure. The forward P/S multiple on this chart clearly demonstrates valuation volatility, with the metric reaching 2.40. While geopolitical tensions and disruptions in biomaterial logistics are hindering growth, a strategic alliance with AstraZeneca ensures a steady flow of R&D investment.

Cellectis - Prakiraan rega marang pendapatan CLLS (periode 04.07.2022 - 13.11.2026)

cellectis.com - rincian analitis lan metrik utama (CLLS)

- rega pasar lan target rega analis:

Bagan rega Cellectis|CLLS - Bagan rega target

- statistik kapitalisasi pasar:

Biji pasar CLLS|CLLS - Nilai Dipunlarasaken Utang lan Kas

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Cellectis S.A.|CLLS - Nilai Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku cellectis.com|CLLS - Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- rincian asil keuangan lan kelipatan valuasi:

CLLS - Bathi pungkasan|Proyeksi bathi mangsa ngarep Cellectis S.A.|CLLS - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Cellectis|CLLS - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA CLLS|CLLS - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Cellectis S.A.|CLLS - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan cellectis.com|CLLS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Cellectis S.A.

- data pendapatan lan penerimaan dodolan:

CLLS - Dodolan perusahaan|Prakiraan volume dodolan Cellectis|CLLS - Rega marang dodolan|Rasio rega marang prakiraan pendapatan CLLS

Analisis wiwitan perusahaan:Cellectis Biotherapeutics (CLLS)

This indicator reflects the market value of Cellectis S.A. (CLLS) relative to expected revenue, allowing for an assessment of the degree of optimism currently priced in regarding future cash flows. By analyzing the business's forward P/S, an investor can compare market expectations with the effectiveness of management's strategy for implementing CAR-T technologies and the quality of their partnerships with pharmaceutical behemoths.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Legend Biotech Corporation LEGN|Sana Biotechnology Inc - Rasio rega marang prakiraan pendapatan|AUTL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ALLO (Allogene Corp)|RNAC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan cariboubio.com CRBU|TIL (Instil Bio) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Genenta GNTA|Rasio rega marang prakiraan pendapatan Century Therapeutics (IPSC)|jaspertherapeutics.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S SNTI (Senti Biosciences)|Adaptimmune Therapeutics plc (ADAP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CERO: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan TCRT (Alaunos Therapeutics)|ACHL (achillestx.com) - Multiplikator forward rega marang pendapatan|CRGX: Rasio rega marang pendapatan sing dikarepake|PSTX (Poseida Therapeutics) - Multiplikator Forward P/S|TSVT: Rega forward marang dodolan|Multiplikator Forward P/S GRCL